PRKAA1 and prostate cancer: Intriguingly, compared with PC-3 sh-NC cells, PC-3 sh-Atg5 cells failed to restore the expression of p-AMPK and p-mTOR even in the presence of CAR, indicating that CHRM1 activates AMPK/mTOR pathway by targeting Atg5 in the prostate cancer cells (Figures 6(c) and 6(d)).